Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin for SAM in Nigeria
NCT05473234Phase 3Terminated
- Sponsor
- University of California, San Francisco
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin in severe acute malnutrition (SAM) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Weight Gain at 8 Weeks. Started Oct 2022; status: terminated.
02
Drugs
azithromycin
03
Conditions
severe acute malnutrition (SAM)
Beyond the preview
Go deeper on NCT05473234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473234.